Hormonal
GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.
GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.
The dual GLP-1 and GIP analog tirzepatide has demonstrated the greatest reduction in weight, with a 20.9% weight loss achieved with tirzepatide 15 mg weekly at 72 weeks... A 3-year trial of liraglutide in those with pre-diabetes and obesity demonstrated reductions in diabetes diagnosis by 70% and increased reversion to normoglycemia by 80% compared to placebo.
Why this rating
Based on multiple large-scale, randomized, placebo-controlled trials (RCTs) with thousands of participants (e.g., SURMOUNT, STEP, SCALE).
Source
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Andrew-Hyun Lee et al. · Healthcare · 2026
DOI 10.3390/healthcare14060734
More from this paper
- GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.Strong
- GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.Good
- GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →